Close

Rodman & Renshaw Starts Oasmia Pharmaceuticals (OASM) at Buy

September 12, 2016 7:27 AM EDT Send to a Friend
Rodman & Renshaw initiated coverage on Oasmia Pharmaceuticals (NASDAQ: OASM) with a Buy rating and a price target of $6 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login